Over the last 30 years, an abundance of studies have clearly demonstrated that 2,3,7, 8-tetrachlorodibenzo-p-dioxin (TCDD) is extremely toxic to experimental animals (1) (2) (3) . Fish and wildlife are also sensitive to the toxic effects of this chemical (4) . TCDD is carcinogenic in male and female rats and mice, male hamsters, and male and female fish (5, 6) . Reproductive and developmental toxicity has been observed in all experimental animals tested. Immunotoxic effects occur in mice, rats, and nonhuman primates exposed to low doses of TCDD (7) . Evidence to date indicates that the actions of TCDD are mediated by the Ah receptor (8, 9 ) which functions as a signal transducer and transcription factor. In many ways the actions of the Ah receptor are similar to those of the steroid hormone receptors (10, 11) , although the Ah receptor is not a member of this superfamily of proteins (12, 13) . Other halogenated dibenzo-p-dioxins and dibenzofurans substituted in all four lateral positions also have high binding affinity to the Ah receptor and induce the same spectrum of toxicity as TCDD (14) . In addition, certain polyhalogenated biphenyls, naphthalenes, and diphenyl ethers are Ah receptor agonists. Humans are exposed to complex mixtures of these chemicals; estimates of daily exposure to TCDD or "dioxinlike" (all 2,3,7,8-halogenated dibenzo-p-dioxins and dibenzofurans as well as the dioxinlike polychlorinated biphenyls) chemicals is 3-6 pg TCDD equivalents/kg/day in the United States (15, 16) . The subclass of the polyhalogenated aromatic hydrocarbons with dioxinlike activity are referred to as dioxins in this article.
Although the toxic effects of dioxins in experimental animals are unequivocal, their toxic effects in humans are less certain. Chloracne is the only toxic effect induced by dioxins for which there is unequivocal evidence linking exposure to effect in humans (17) . The uncertainty of other toxic effects of dioxins in humans is due to the scarcity of human populations with high dose exposures, limited data on the body burdens of dioxins present in these populations, the difficulty in assessing sensitive toxic endpoints in humans, and the lack of knowledge about likely, but unknown, genetic factors that may influence the relative susceptibility of individuals. Dioxins produce some of the same biochemical alterations in humans and experimental animals (18) . Several recent epidemiological studies suggest an association between dioxin exposure and increased incidence of cancer (19) (20) (21) (22) (23) and increased incidence of altered glucose tolerance in exposed populations (24, 25) . One way to determine the strength of an association between dioxin exposure and a toxic effect in humans would be to compare the dose of dioxin that is required to produce an effect in animals to the dose of dioxin in humans that is associated with a similar toxic effect. While it is clear that for some toxic effects, such as lethality and body weight loss, there are marked species differences in susceptibility to dioxins, many recent studies have also noted that for other endpoints, such as reproductive and developmental effects, most animal species respond at similar doses (9, 26) . Thus, the dose of dioxin that produces a particular effect in experimental animals might be expected to be similar to the dose of dioxin associated with that same effect in humans.
Although the hypothesis that toxic doses of dioxins in animals and humans are similar for most responses is theoretically testable using data from accidentally exposed human populations, there are some difficulties. In particular, it is often difficult to determine the human dosage at the time of exposure. In experimental studies, animals are administered a known amount of dioxin and evaluated at a specific time after the treatment. In humans the actual exposure is unknown and often difficult to estimate. Several epidemiological studies determined serum concentration of dioxins in exposed and control populations (19) (20) (21) (22) (23) (24) (25) . Although the dose to the individuals in these studies is uncertain, the body burdens of dioxins in these populations can be estimated at a specific point in time. In addition, serum and tissue dioxin concentrations from populations in the United States with-out any unusually high exposures have been reported from several different laboratories (27) (28) (29) (30) . All humans in industrialized countries are presumed to carry a body burden of dioxins based primarily on consumption of minute quantities of dioxin in the food supply. Here (2, 14, 26) . To account for exposure to additional dioxins, the toxic equivalency factor method (TEF) was used (14, (35) (36) (37) (38) . TEFs are relative potency factors used to convert the amount of dioxins in a sample to TCDD equivalents or TEQs (14, (35) (36) (37) (38) Body burden estimates in populations exposed to background levels of dioxins were based on published studies that measured serum concentrations of 2,3,7,8-chlorine substituted dibenzo-p-dioxins (CDDs) and dibenzofurans (CDFs) and dioxinlike PCBs in populations with no unusually high exposure to dioxins (27) (28) (29) (30) 39) . Serum concentrations of CDDs and CDFs have been measured in a number of different populations from several studies. Schecter (27) presented data indicating that the average whole-blood CDD/CDF concentration in U.S. (n = 100) and German (n = 85) populations were similar when presented on a TEQ basis (41 and 42 ng TEQ/kg whole blood, lipid adjusted). More extensive studies of U.S. populations indicate that the national average for serum CDD/CDF concentrations is 28 ng TEQ/kg serum lipid (39) . Much 
u aThe data and methodology used to determine each value are presented in the appendix under the letter indicated. mice (61) , respectively, which is within the range of background human body burdens of 13 ng TEQ/kg body weight. Disposition of dioxins is dose dependent in animals and humans (62) . The body burden necessary for hepatic sequestration is similar for rats and humans (624.
In animals, the body burden of TCDD that produces a carcinogenic effect ranges from 944 ng TCDD/kg body weight in mice (70) to 137,000 ng TCDD/kg in hamsters (68) ( Decreased birth weights were reported in children born to women exposed during the Yu-Cheng incident (18, 56) . These women were highly exposed and had an average body burden of approximately 2,130 ng TEQ/kg body weight. Body burdens of dioxins in experimental animals that decrease birth weight range from 400 to 2,000 ng TCDD/kg body weight in rats and hamsters (73, 74) (Table 3) .
Children of the Yu-Cheng mothers are not only smaller at birth but remain smaller throughout childhood compared to children of unexposed women (63) . In rats, pups of dams exposed to 1,000 ng TCDD/kg body weight not only have decreased birth weights but consistently weigh less than controls up to 63 days of age, though they do recover upon reaching sexual maturity (75) .
The Yu-Cheng children also exhibit delayed developmental milestones (64, 65) .
Behavioral effects after perinatal TCDD exposure have been observed in rhesus monkeys born to mothers exposed to approximately 5 ppt TCDD in the diet (66 (24, 25) . Decreased serum glucose in rats occurs at body burdens 14-20 times higher than the increased incidence of diabetes and altered glucose tolerance in humans.
Environmental Health Perspectives * Volume 103, Number 9, September 1995 (82, 83) . Enhanced viral susceptibility, as measured by increased mortality, occurs in mice at body burdens of approximately 10 ng TCDD/kg (84) , which is equivalent to the body burden seen in unexposed humans and approximately twice the level in untreated mice. Effects such as increased incidence of endometriosis in rhesus monkeys (85) and decreased sperm count in offspring of rats treated with TCDD (74, 86) (1-3) . Because of this large variability in lethal effects, there has been an expectation that large species differences exist for all other effects. The data presented in the tables indicate that for a particular effect, some species may be extremely sensitive and some may be resistant, but many species respond at similar doses (i.e., within an order of magnitude). All experimental mammalian species examined respond to most of the adverse effects of dioxins at some dose. It is possible that humans may be resistant to some of the toxic effects of dioxins, but it seems highly unlikely, given the data currently available, that humans are refractory to all of the toxic effects of these chemicals.
Dioxins are unequivocally potent toxicants in experimental animals, yet the human health effects of exposure to these chemicals remain controversial. Comparisons of human and animal body burdens alone cannot prove a cause-and-effect relationship between toxicity and exposure in humans observed in an epidemiological study. However, this information can be used to increase or decrease our confidence that a particular adverse health effect observed in an epidemiological study was associated with the exposure to dioxins.
In addition, the present analysis required several assumptions in estimating both animal and human body burdens. These assumptions were required due to the lack of complete data on pharmacokinetics, toxic equivalency factors, species extrapolation, and, for humans, lack of information on daily dose or exposures. Hence, the information presented here can be used to direct research efforts to provide more accurate information on these topics.
There are some uncertainties associated with the assumptions used to estimate body burdens of dioxins in animals and humans. Unlike the experimental animal toxicology studies examined, humans are exposed to multiple chemicals. However, in the epidemiological studies, many of these chemicals interact with the Ah receptor as either agonists, partial agonists, or possibly antagonists. Assumptions of the relative potency of the chemicals and their distribution in the humans will result in uncertainties that are difficult to quantify given the present database. However, these uncertainties are likely well within an order of magnitude because body burdens of TCDD alone represent 10% of the total TEQ body burden due to all the PCDDs, PCDFs, and PCBs (Table 2) .
Human body burdens are estimated using the TEF methodology. The TEF values derived by the U.S. EPA and the World Health Organization were based on scientific judgment as well as experimental data (37, 38) . In setting a TEF value, more weight was given to long-term, in vivo studies than to in vitro or acute in vivo studies (14, (36) (37) (38) . In fact, although wide ranges of TEF values have been reported for specific congeners, the variability is within a factor of 10 when the in vivo data are used to set the TEF value (14, 37, 38) .
The TEF methodology assumes additivity of toxic potential. (95) (96) (97) (98) .
Using the assumption that dioxins are equally distributed in the body lipid may underestimate the body burden of these chemicals due to chemical and dose-dependent sequestration in the liver. The magnitude of underestimation can be determined if several assumptions are used: that the liver/fat ratio for all dioxins is 15 and that liver is 10% of the body weight and is 10% lipid by weight. A liver/fat ratio of 15 , as determined for the hexachlorodibenzofurans in humans, is used as a worst-case scenario for hepatic sequestration. Using these assumptions, the present estimate of dioxin TEQ body burdens in background populations will change from 13 to 21 ng TEQ/kg body weight. Hence, the assumption that dioxins are equally distributed in body lipid may slightly underestimate the body burdens of these chemicals, but the magnitude of error will be less than a factor of two. A better understanding of the pharmacokinetic properties for this class of compounds in humans is dearly indicated.
Chloracne has been described as the hallmark of dioxin toxicity in humans (17) . Dioxin exposure in several animal species results in a chloracnegenic response and the body burdens which produce this response in animals are similar to the body burdens of dioxins in humans with chloracne. The chloracnegenic response has been thought to be a relatively high-dose phenomenon; however, the variation in human sensitivity to the chloracnegenic effects of TCDD is almost two orders of magnitude. For example, there are individuals who developed chloracne at body burdens approximately three times background (51) . In contrast, there are subjects with body burdens of 1450 ng TEQ/kg body weight who have not developed chloracne (51) . These data suggest that humans differ widely in sensitivity to the chloracnegenic actions of dioxins.
There are two points of caution when interpreting the chloracne data. First (56) . Birth weights were negatively correlated with PCDF levels in these individuals (56) . Other effects such as induction of arylhydrocarbon hydroxylase activity, a marker for CYPlAI, were not correlated with either the polychlorinated dibenzofurans or the PCB concentrations, but decreased placental EGF receptor autophosphorylation was correlated with total PCB concentrations (56) . However, due to the nature of the exposure, patients with high levels of dibenzofurans will likely have high levels of PCBs, making such correlations difficult to interpret. Also, the presence of dioxinlike and non-dioxinlike PCBs adds to the complexity of these correlations.
We compared the body burdens of dioxins in the Yu-Cheng population to body burdens in experimental animals to determine the role of dioxins in the toxic effects seen in these individuals. Women who were pregnant at the time of exposure or became pregnant thereafter had children with lower birth weights compared to unexposed women, and the decrease in size persisted years after birth (63) . Body burdens in the Yu-Cheng mothers were estimated at 2130 ng TEQ/kg. In experimental animals the body burdens that result in decreased birth weights range from 400 to 2000 ng TCDD/kg, while decreased growth occurs in rats at 1,000 ng TCDD/kg. The similarities between the body burdens in animals and humans suggests that dioxins may play a role in the decreased birth weights.
The behavioral effects of dioxins have not been thoroughly studied in experimental animals. One study reported deficiencies in object learning in rhesus monkeys prenatally exposed to TCDD. Delayed developmental milestones were seen in children born to Yu-Cheng mothers, but the body burdens are approximately 51 times higher in humans than in the monkeys. There is recent evidence that some of the non-dioxinlike PCBs may have neurotoxic actions (101) . The absence of studies in experimental animals examining the developmental behavioral toxicity of dioxins makes it difficult to assess the role of either the dioxins or the non-dioxinlike PCBs in the developmental effects of the children of the Yu-Cheng patients.
In experimental animals, some biochemical changes produced by dioxins occur at lower body burdens than do the toxic effects (57-61,71). Induction of CYPlAl and decreased hepatic EGF receptor are two well-characterized biochemical responses to TCDD. Earlier studies comparing the induction of CYPlAl and decreased EGF receptor in human placenta and rat liver suggested that humans may be more sensitive when compared on a tissuedose basis (18) . However, it is possible that the difference in sensitivity is not entirely due to species differences but due to altered tissue sensitivity. For example, induction of GCYPlA1 is similar in lung, liver, and skin of mice based on administered dose (102) . In contrast, when the sensitivity of these tissues is compared on a tissue-dose basis, the lung is much more sensitive than the liver or skin (102) . The present study indicates that humans and rats are equally sensitive to TCDD-induced biochemical changes when compared on a total body burden. Thus, when comparing the relative sensitivity of human or animal tissues to TCDD-induced biochemical changes, it may be more appropriate to compare body burdens than tissue concentrations. In addition, these data provide support for our approach.
TCDD is clearly carcinogenic in experimental animals. All species and both sexes of experimental animals that have been chronically exposed to TCDD exhibit a dose-dependent increased incidence of tumors (5) . Several recent epidemiological studies have indicated an association between TCDD serum concentrations and increased incidence of tumors (19) (20) (21) (22) (23) . Body burdens in rats and mice with increased tumors are comparable to the body burdens in the human cohorts that have increased incidence of tumors thought to be associated with dioxin exposure. Although these data are not conclusive, they are consistent with the hypothesis that exposure to TCDD was an important factor in the increased incidence of tumors in these cohorts. It is interesting to note that based on body burdens, mice are more sensitive to the carcinogenic effects of TCDD than are rats.
Carcinogenic responses are seen in hamsters, but the carcinogenic doses produce body burdens 46-1,300 times that seen either in humans, rats, or mice. Hamsters are insensitive to the lethal effects of dioxins, and they may also be less sensitive to the carcinogenic response. However, responses such as cancer are dose dependent as well as time dependent. Thus, the apparent differential sensitivity of the hamster may be due to differences in the dose-time regimens used in the hamster compared to the rat and mouse studies. It would be useful to compare these species under similar exposure protocols.
Decreases in serum testosterone have been reported in a National Institute of Occupational Safety and Health (NIOSH) cohort (41) . There was a decrease in testosterone concentrations in individuals with serum concentrations of TCDD as low as 20 ppt at the time of tissue sampling, which is 3-4 times background TCDD levels and only a 33% increase over total average body burdens. Although the decrease in testosterone concentrations was statistically significant, the decrease was minor, and average levels were still within the normal range. In addition, a clear association between serum TCDD concentrations and effect was not readily apparent in the data (41) . If differences in exposure patterns in the individuals are taken into account by back-calculating serum TCDD concentrations to the time of exposure, there is a clearer association between serum TCDD concentrations and lower testosterone concentrations. Here the lowest serum TCDD concentration associated with decreased testosterone concentration is 140 ppt (200 ppt TEQ). In experimental animals, high doses of TCDD decrease testosterone concentrations in rats at a body burden of 12,500 ng TCDD/kg body weight (73) . These data suggest that some humans may be approximately 280 times more sensitive to the testosteronedecreasing effects of dioxins compared to rats. Alternatively, the decreased testosterone levels in the NIOSH cohort could be related to the concomitant exposure to other chemicals involved in the manufacturing process. Future studies examining the sensitivity of other species to the testosterone-decreasing effects of dioxins and epidemiological studies of other populations may provide additional information to adequately assess the association between dioxin exposure and decreased testosterone concentrations in some human populations.
Many of the effects of TCDD have been studied following an acute exposure in experimental animals. In contrast, humans receive low daily doses of these chemicals. One of the assumptions in extrapolating these effects to humans is that the effects are solely related to body burdens. For some of these endpoints, such as decreased testosterone, this assumption has not been adequately tested. Effects such as cancer are clearly related to both dose and time. It is possible that, in addition to dose and body burden, length of exposure may also have a significant effect on toxicity. Analysis of the area under the total body concentration-time curve may be a more appropriate marker for dose, and analysis of these data sets is ongoing.
The clinical significance of some of the endpoints studied is uncertain. Induction of CYPlAI and CYP1A2 by TCDD are some of the most sensitive markers of dioxin exposure, yet their relevance to toxicity is unclear. Recent studies have suggested an association between PAH exposure and CYPlA1/lA2 induction for lung and colorectal cancer and athelerosclerosis (103) (104) (105) . However, these associations are speculative and not proven. At present, one could conclude that low doses of dioxins produce effects such as enzyme induction in experimental animals and that humans are exposed to levels of dioxins that induce CYPlA1/lA2 in experimental animals, but the relationship between these effects and disease are uncertain.
One of the most sensitive targets for TCDD toxicity in experimental animals is the immune system. Immune alterations, including increased viral sensitivity in mice and altered lymphocyte subsets in marmosets, have been reported at body burdens equivalent to human background exposures. However, the evidence for immunotoxicity of dioxins in humans is inconclusive. There are reports of subtle immune alterations in populations heavily exposed to dioxins. The incidence of intestinal and upper respiratory tract infections correlated with chloracne state and increased with increasing serum TCDD concentrations (106) . One year after the Yu-Cheng poisoning episode, patients exhibited decreases in percentage of total T-cells, active T-cells, and T-helper cells, which recovered by the 3-year follow up study (107) . Recent studies of occupationally exposed individuals with slightly elevated body burdens of approximately 72 ng TEQ/kg showed no alterations in lymphocyte subsets (108) . However, in mice, a dose of TCDD that suppresses the antibody response to sheep red blood cells is not associated with alterations in lymphocyte subsets (109) . Thus, immune function may be altered without altering lymphocyte subsets. Although some of these data suggest that the human immune system may be sensitive to the effects of dioxins, our present understanding of immunology does not support a conclusion that these alterations are or are not clinically significant.
The present study indicates that in vitro similar responses are seen in human and animal tissues after similar dioxin exposure. Human populations exposed to high concentrations of dioxins exhibit symptoms that are similar to the signs of toxicity seen in some experimental animals exposed to dioxins. These effects are seen at equivalent body burdens, strongly indicating that dioxins are responsible for some of these toxic effects in humans. For most of the toxic effects of dioxins, background exposure is well below those associated with overt toxicities. However, the background level used in this evaluation (13 ng TEQ/kg body weight) is an average background. Body burdens of dioxins appear to be log-normally distributed in humans (110) 
